Abstract:At present, the factors influencing Tuberculosis (TB) treatment effectiveness in HIV/TB co-infected patients need to be supported by more substantial real-world evidence. A retrospective study is conducted to fill the vacancy. 461 TB patients with HIV are defined as 742 samples according to each TB detection period. 7788 valid treatment records corresponding to 17 drug compositions for TB and 150 clinical indicators with more than 100 records are used to conduct data mining with consensus clustering, Fisher’s exact test, stratified analysis, and three modeling approaches, including logistic regression, support vector machine, and random forest. We find that A CD4+ T cell count of 42 cells per μL may serve as a sensitive classification standard for the immune level to assist in evaluating or predicting the efficacy of TB ( P =0.007); Rifabutin and levofloxacin alone or in combination may be more effective than other first- and second-line anti-TB agents in combination ( P =0.037); Samples with low immune levels (CD4≦42) may be more resistant to first-line TB drugs ( P =0.049); Age ( P =0.015), bicarbonate radical ( P =0.007), high-density lipoprotein cholesterol ( P =0.026), pre-treatment CD8+ T cell count ( P =0.015, age<60, male), neutrophil percentage ( P =0.033, age<60), rifabutin ( P =0.010, age<60), and cycloserine ( P =0.027, age<60) may influence the TB treatment effectiveness; More evidence is needed to support the relationship between pre-treatment clinical indicators or drug regimens and TB treatment effectiveness (The best AUC is 0.560∼0.763); The percentage of lymphocytes ( P =0.028) can be used as an effective TB therapeutic target. These perspectives supplement knowledge in relevant clinical aspects. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was funded by Funds for the key project of the Shanghai Public Health Clinical Center (KY-GW-2023-15); Shanghai Science and Technology Commission Medical Innovation Research Special Major Project (21Y31900400); Shanghai Science and Technology Commission Shanghai infectious diseases (AIDS) Clinical Medical Research Center Project (20MC1920100); Shenkang Hospital Development Center Clinical Science and Technology Innovation Project (SHDC22021317); Shanghai Municipal Science and Technology Critical Special Project "Research on Key Technologies for Prevention and Control of Major Sudden Infectious Diseases" (ZD2021CY001); Shenkang Hospital Development Center Clinical Research Basic Support Project (SHDC2020CR6025). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics Committee of Shanghai Public Clinical Center(No. 2020-S110-01) gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

Association between TB delay and TB treatment outcomes in HIV-TB co-infected patients: a study based on the multilevel propensity score method

Diagnostic delay, treatment duration and outcomes since the implementation of integrated model of tuberculosis control and their associated factors in a county in East China

Effect of Different Interventions for Latent Tuberculosis Infections in China: a Model-Based Study

Cut-off Points of Treatment Delay to Predict Poor Outcomes among New Pulmonary Tuberculosis Cases in Dalian, China: A Cohort Study

Association between diagnostic delay and prognosis of pulmonary tuberculosis in Shandong, China: a retrospective study

Assessing heterogeneity of patient and health system delay among TB in a population with internal migrants in China

Delayed diagnosis of tuberculosis in patients with diabetes mellitus co-morbidity and its associated factors in Zhejiang Province, China

A Retroactive Study on Factors Influencing the Efficacy of Treatment for Tuberculosis Patients with HIV: based on the data from 2010 to 2020 in Shanghai, China

Factors Associated with Delayed Tuberculosis Diagnosis in China

Delay analysis of pulmonary tuberculosis in the eastern coastal county of China from 2010 to 2021: evidence from two surveillance systems

Comorbidity and drug resistance of smear-positive pulmonary tuberculosis patients in the yi autonomous prefecture of China: a cross-sectional study

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Diagnostic Delays in Access to Tuberculosis Care in Counties with or Without the National Tuberculosis Control Programme in Rural China

Diagnostic Delay and Its Factors in Access to Tuberculosis Care in Northern Rural Jiangsu Province

Analysis of care-seeking and diagnosis delay among pulmonary tuberculosis patients in Beijing, China

Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China

Patient delay, diagnosis delay, and treatment outcomes among migrant patients with tuberculosis in Shanghai, China, 2018-2020: a mixed-methods study

Insufficient tuberculosis treatment leads to earlier and higher mortality in individuals co-infected with HIV in southern China: a cohort study

Patient pathway analysis of tuberculosis diagnostic delay: a multicentre retrospective cohort study in China

Comparison of Delay in Tuberculosis Diagnosis Between Migrants and Local Residents in an Eastern County of China: An Analysis of the Electronic Data Between 2015 and 2019

Treatment Quality and Outcome for Multidrug-Resistant Tuberculosis Patients in Four Regions of China: a Cohort Study.